Agenus Inc. (Nasdaq: AGEN) has acquired biopharmaceutical company 4-Antibody AG.
The target develops the Retrocyte Display technology platform, which aims to help regulate immune response to cancers and other diseases.
The purchase price for the transaction could be more than $40 million, depending on 4-Antibody achieving certain milestones.
Agenus, headquartered in Lexington, Mass., expects the deal to allow it to develop therapies for cancer. The company’s main focus is on anti-cancer vaccines.
Agenus received more than $9 million in venture capital funding from Downsview Capital, Hudson Capital Management and Iroquois Capital in 2009.
Other recent cancer biotechnology deals include Senesco Technologies Inc.’s merger with Fabrus Inc. and Imugene’s (ASX: IMU) deal for Biolife Science Qld Ltd.